home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

16.05 +0.22 (+1.39%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

These 2 Healthcare Stocks Have Doubled in 2023

February 01, 2023

Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks.

Via MarketBeat

Aurinia Announces PTAB Has Terminated Inter Partes Review

January 25, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

January 24, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Shares of Aurinia Pharmaceuticals Soared This Week ↗

January 06, 2023

A patent settlement and improved financials sent the stock soaring.

Via The Motley Fool

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

January 06, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals ↗

January 04, 2023

Via Benzinga

Tesla, Amazon, Apple, Aurinia Pharma, Vera Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 03, 2023

Major Wall Street indices closed in the red on Tuesday, the first trading day of 2023, as concerns over rising rates and inflation still seem to drive investor sentiments.

Via Benzinga

Why Is Aurinia Pharmaceuticals (AUPH) Stock Down 30%? ↗

November 03, 2022

Despite strong Q3 earnings, shares of AUPH stock are in steep decline today after it lowered its full-year sales guidance.

Via InvestorPlace

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 03, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 03, 2023

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Via Benzinga

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

January 03, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

November 30, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals ↗

November 04, 2022

Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗

November 04, 2022

Upgrades

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

November 03, 2022

We're starting off the day with a look at the latest news behind the biggest pre-market stock movers for Thursday morning!

Via InvestorPlace

Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday ↗

November 04, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.

Via Benzinga

Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗

November 03, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.

Via Benzinga

Recap: Aurinia Pharmaceuticals Q3 Earnings ↗

November 03, 2022

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

November 03, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Earnings Preview For Aurinia Pharmaceuticals ↗

November 02, 2022

Aurinia Pharmaceuticals (NASDAQ:AUPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

October 28, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

October 27, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗

October 24, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

Via Benzinga

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

September 20, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

September 19, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

NASDAQ: AUPH Long Term Investor Alert: Investigation of Potential Wrongdoing at Aurinia Pharmaceuticals Inc. ↗

August 15, 2022

San Diego, CA -- (SBWIRE) -- 08/15/2022 -- Certain directors of Aurinia Pharmaceuticals Inc. are under investigation over possible breaches of fiduciary duties.

Via SBWire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com